Literature DB >> 25531078

Avian influenza (H7N9) virus infection in Chinese tourist in Malaysia, 2014.

Timothy William, Bharathan Thevarajah, Shiu Fee Lee, Maria Suleiman, Mohamad Saffree Jeffree, Jayaram Menon, Zainah Saat, Ravindran Thayan, Paul Anantharajah Tambyah, Tsin Wen Yeo.   

Abstract

Of the ≈400 cases of avian influenza (H7N9) diagnosed in China since 2003, the only travel-related cases have been in Hong Kong and Taiwan. Detection of a case in a Chinese tourist in Sabah, Malaysia, highlights the ease with which emerging viral respiratory infections can travel globally.

Entities:  

Mesh:

Year:  2015        PMID: 25531078      PMCID: PMC4285235          DOI: 10.3201/eid2101.141092

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


Human infection with avian influenza (H7N9) virus was first reported from China in 2013 (). Since then, ≈400 cases have been diagnosed in China and some in Hong Kong and Taiwan. Most patients were older adults with severe community-acquired pneumonia; risk for admission to an intensive care unit is 83%, and risk for death is 27%–36% (,). We report avian influenza (H7N9) virus infection outside greater China, in a Chinese tourist visiting Sabah, Malaysia.

The Study

The patient was a 66-year-old woman from Guangzhou, Guangdong Province, China. She was not obese and had no relevant medical history. She worked on a household farm that cultivated vegetables but not animals. On January 30, 2014, she purchased from a poultry market 3 live chickens, which she slaughtered and cooked that day. According to the patient, these chickens and those at the market appeared healthy; she reported no contact with other birds. Two days later, she experienced cough, myalgia, and fever and consulted a local doctor who treated her symptomatically without performing laboratory or radiologic investigations. The woman subsequently went on holiday and flew to Peninsular Malaysia on February 4 and to Sabah, Malaysian Borneo, on February 6. She had persistent fever, worsening productive cough, arthralgia, abdominal pain, and diarrhea. On February 7, she sought care at Tuaran District Hospital for acute respiratory distress; she was intubated and transferred to a private specialist hospital in Kota Kinabalu, Sabah, Malaysia. At admission, she was placed in a negative-pressure isolation room with a portable high-efficiency particulate air filter that removes air particles >0.3 μm; staff observed airborne-transmission precautions. Abnormal findings during initial examination were blood pressure 70/40 mm Hg, heart rate 96 beats/minute, and generalized crackles heard on lung auscultation. Hematologic, biochemical, and arterial blood gas results from samples obtained at admission (while the patient received 100% oxygen by mechanical ventilation) are summarized in the Table. Chest radiographs showed extensive dense pulmonary consolidations. The patient received dopamine, ceftriaxone, azithromycin, and oseltamivir. Culture of blood collected at admission grew methicillin-susceptible Staphylococcus aureus; tracheal aspirate results were negative, and cloxacillin was administered. The patient received ventilatory support with synchronized intermittent mandatory ventilation with a positive end-expiratory pressure of 10 cm H2O. On February 13 she was given methylprednisolone, which was discontinued on February 20 and replaced with oral prednisone on February 21. Ventilatory requirements gradually decreased, and she was extubated on February 22, after blood results normalized and oseltamivir was discontinued. However, on February 23, a low-grade fever and Pseudomonas aeruginosa bacteremia were found, and the patient was given meropenem and piperacillin-tazobactam. On February 28, her respiratory symptoms and fever recrudesced after discontinuation of oral prednisone. On the same day, oseltamivir and prednisone were given along with inhaled zanamivir, intravenous cefepime, and ciprofloxacin; her condition gradually improved. On March 7, oseltamivir and zanmivir were discontinued; on March 13, the patient was considered well and was discharged with a tapering dose of prednisone. She returned to China on March 16. A time line of her travel and hospital course is detailed in the Figure.
Table

Hematologic and biochemical values for Chinese patient with avian influenza (H7N9) virus infection at hospital admission, Malaysia, February 7, 2014

Laboratory test
Value (reference range)
Blood counts
Hemoglobin, g/dL 12.7 (12.0–18.0)
Leukocyte, cells/mm3 10.2 × 103 (3.5–12 × 103)
Neutrophils, cells/mm3 9.2 × 103 (2.5–7.5 × 103)
Lymphocytes, cells/ mm3 276 (1.0–4.8 × 103)
Platelets, cells/mm3
150 × 103 (150–400 × 103)
Serum tests
Creatinine, mmol/L 87 (50–110)
Sodium, mmol/L140 (135–145)
Potassium, mmol/L3.6 (3.5–5.1)
Chloride, mmol/L 102 (96–106)
Total protein, g/L 57 (60–80)
Albumin, g/L 23 (35–50)
Globulin, g/L 34 (25–40)
Total bilirubin, μmol/L 6.6 (2–28)
Alanine aminotransferase, IU/L 92 (7–40)
Aspartate aminotransferase, IU/L 208 (5–35)
C-reactive protein, mg/L
263.76 (<3)
Arterial blood measurements*
pH 7.41 (7.35–7.45)
Partial pressure of oxygen, 
 mm Hg65 (75–100)
Partial pressure of carbon 
 dioxide, mm Hg 4.3 (38–42)
Lactate, mmol/L 1.4 (0–2)

*Obtained while patient was receiving 100% oxygen.

Figure

Time line of the travel dates and hospital course of avian influenza (H7N9) virus infection in Chinese tourist to Malaysia.

*Obtained while patient was receiving 100% oxygen. Time line of the travel dates and hospital course of avian influenza (H7N9) virus infection in Chinese tourist to Malaysia. According to Malaysian Ministry of Health criteria, infection with influenza (H7N9) virus is suspected in persons with severe respiratory illness and a history of travel from affected areas in China. For this patient, on February 7, clinicians from district and specialist hospitals sent throat swabs in viral transport media (Copan Diagnostics, Inc., Murrieta, CA, USA) to the National Influenza Centre at the Institute of Medical Research in Kuala Lumpur for virus studies. Real-time reverse transcription PCR was used to test for the following viruses, as described (): influenza A, influenza B, influenza A(H1N1) pdm09, influenza H1 seasonal, influenza H3 seasonal (all by using Centers for Disease Control and Prevention protocols []), influenza H7 avian (Centers for Disease Control and Prevention, Chinese National Influenza Centre [], and local protocols), and influenza N9 (Chinese National Influenza Centre protocol). Results were positive for influenza A and influenza H7 and N9: results remained positive on repeated swab samples collected on February 13 and 22. Sequencing of the hemagglutinin and neuraminidase genes revealed that these strains were closely related to strains from Guangzhou and Guandong () but did not reveal the mutation associated with oseltamivir resistance: R294K (N9 numbering) (). No virus was detected in samples collected on February 26 and 28. During February 7–16, officials from the Malaysian Public Health Department and Sabah State Health Department identified 191 persons who had had contact with the patient; 6 were symptomatic, but nasopharyngeal swab specimens were negative for influenza. The symptomatic contacts included tour group members and personnel from various hotels, restaurants, airlines, tourist destinations, airports, and hospitals.

Conclusions

The rapid diagnosis of avian influenza (H7N9) virus infection outside China and Taiwan in a Chinese tourist traveling to Sabah, Malaysia, highlights the value of a high index of suspicion by medical staff, awareness and adherence to national guidelines, and good laboratory services (). The clinical features of the patient were similar to those previously reported from China: median age of affected persons was 61 years, and >80% of patients reported exposure to live poultry and experienced pneumonia or respiratory failure (). Virus was detected by reverse transcription PCR after the patient had received oseltamivir for 2 weeks, as has been reported (), although the significance of prolonged detection is unclear because the patient’s clinical condition improved markedly, no oseltamivir resistance mutations were found (), and virus persistence may have be associated with steroid use. The patient’s condition deteriorated after taking oseltamivir 1 week after symptom onset and ventilatory requirements increased, possibly because of secondary S. aureus infection, a well-known complication of influenza (). The patient was given methylprednisolone after a week of hospitalization; although she subsequently improved, it was unclear if this was in response to the antimicrobial drugs, the corticosteroids, or the natural course of the infection. Anecdotal reports describe clinical improvement of a patient in Taiwan with influenza (H7N9) pneumonia after receipt of corticosteroids (), but such improvement has not been supported by larger studies of influenza (H7N9) patients () or studies of adults in Vietnam infected with avian influenza (H5N1) virus (,). Of the ≈400 cases of human avian influenza (H7N9) infection diagnosed in China since 2003, the only travel-related cases were in Hong Kong and Taiwan, which have close geographic, economic, and cultural ties to China and extensive bidirectional travel. This case highlights the ease with which emerging viral infections can travel globally. On a map of recent air travel from China, major destinations identified () were Taiwan, Hong Kong, Malaysia, and Singapore; dozens of flights went to major cities in Europe and North America, which received hundreds of visitors directly from China weekly. In the first 3 quarters of 2013, an estimated 72.5 million tourists left China (). To ensure accurate identification and appropriate management of emerging novel respiratory viral infections, clinicians in destination countries need to obtain detailed travel histories from tourists and returning travelers The influenza (H7N9) virus is not easily transmissible among humans, and our investigations did not find any evidence of spread to the patient’s fellow travelers, medical staff, or other contacts. However, the virus has the potential to adapt to mammalian hosts over time (,). Clinicians and public health authorities need to be alert to the latest epidemiologic information on emerging respiratory viruses; local capacity to isolate, diagnose, and treat illness in travelers with unusual respiratory viral infections is also needed.
  12 in total

1.  Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness.

Authors:  David M Morens; Jeffery K Taubenberger; Anthony S Fauci
Journal:  J Infect Dis       Date:  2008-10-01       Impact factor: 5.226

2.  Epidemiology of human infections with avian influenza A(H7N9) virus in China.

Authors:  Qun Li; Lei Zhou; Minghao Zhou; Zhiping Chen; Furong Li; Huanyu Wu; Nijuan Xiang; Enfu Chen; Fenyang Tang; Dayan Wang; Ling Meng; Zhiheng Hong; Wenxiao Tu; Yang Cao; Leilei Li; Fan Ding; Bo Liu; Mei Wang; Rongheng Xie; Rongbao Gao; Xiaodan Li; Tian Bai; Shumei Zou; Jun He; Jiayu Hu; Yangting Xu; Chengliang Chai; Shiwen Wang; Yongjun Gao; Lianmei Jin; Yanping Zhang; Huiming Luo; Hongjie Yu; Jianfeng He; Qi Li; Xianjun Wang; Lidong Gao; Xinghuo Pang; Guohua Liu; Yansheng Yan; Hui Yuan; Yuelong Shu; Weizhong Yang; Yu Wang; Fan Wu; Timothy M Uyeki; Zijian Feng
Journal:  N Engl J Med       Date:  2013-04-24       Impact factor: 91.245

3.  Emergence of a novel swine-origin influenza A (H1N1) virus in humans.

Authors:  Fatimah S Dawood; Seema Jain; Lyn Finelli; Michael W Shaw; Stephen Lindstrom; Rebecca J Garten; Larisa V Gubareva; Xiyan Xu; Carolyn B Bridges; Timothy M Uyeki
Journal:  N Engl J Med       Date:  2009-05-07       Impact factor: 91.245

4.  Pandemic influenza viruses--hoping for the road not taken.

Authors:  David M Morens; Jeffery K Taubenberger; Anthony S Fauci
Journal:  N Engl J Med       Date:  2013-06-05       Impact factor: 91.245

5.  Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance.

Authors:  Yunwen Hu; Shuihua Lu; Zhigang Song; Wei Wang; Pei Hao; Jianhua Li; Xiaonan Zhang; Hui-Ling Yen; Bisheng Shi; Tao Li; Wencai Guan; Lei Xu; Yi Liu; Sen Wang; Xiaoling Zhang; Di Tian; Zhaoqin Zhu; Jing He; Kai Huang; Huijie Chen; Lulu Zheng; Xuan Li; Jie Ping; Bin Kang; Xiuhong Xi; Lijun Zha; Yixue Li; Zhiyong Zhang; Malik Peiris; Zhenghong Yuan
Journal:  Lancet       Date:  2013-05-29       Impact factor: 79.321

6.  Human infection with a novel avian-origin influenza A (H7N9) virus.

Authors:  Rongbao Gao; Bin Cao; Yunwen Hu; Zijian Feng; Dayan Wang; Wanfu Hu; Jian Chen; Zhijun Jie; Haibo Qiu; Ke Xu; Xuewei Xu; Hongzhou Lu; Wenfei Zhu; Zhancheng Gao; Nijuan Xiang; Yinzhong Shen; Zebao He; Yong Gu; Zhiyong Zhang; Yi Yang; Xiang Zhao; Lei Zhou; Xiaodan Li; Shumei Zou; Ye Zhang; Xiyan Li; Lei Yang; Junfeng Guo; Jie Dong; Qun Li; Libo Dong; Yun Zhu; Tian Bai; Shiwen Wang; Pei Hao; Weizhong Yang; Yanping Zhang; Jun Han; Hongjie Yu; Dexin Li; George F Gao; Guizhen Wu; Yu Wang; Zhenghong Yuan; Yuelong Shu
Journal:  N Engl J Med       Date:  2013-04-11       Impact factor: 91.245

7.  Avian influenza A (H5N1) in 10 patients in Vietnam.

Authors:  Tinh Hien Tran; Thanh Liem Nguyen; Thi Dung Nguyen; Thi San Luong; Phuong Mai Pham; van Vinh Chau Nguyen; Thi Suu Pham; Cong Dong Vo; Thi Quynh Mai Le; Thi Thi Ngo; Bach Khoa Dao; Phuc Phat Le; Thanh Truong Nguyen; Thuy Long Hoang; Viet Tung Cao; Truong Giang Le; Dac Tho Nguyen; Hong Nga Le; Kim Tien Nguyen; Hoang San Le; Van Tuan Le; Dolecek Christiane; Tan Thanh Tran; de Jong Menno; Constance Schultsz; Peter Cheng; Wilina Lim; Peter Horby; Jeremy Farrar
Journal:  N Engl J Med       Date:  2004-02-25       Impact factor: 91.245

Review 8.  H7N9 avian influenza A virus and the perpetual challenge of potential human pandemicity.

Authors:  David M Morens; Jeffery K Taubenberger; Anthony S Fauci
Journal:  MBio       Date:  2013-07-09       Impact factor: 7.867

9.  Human infection with avian influenza A H7N9 virus: an assessment of clinical severity.

Authors:  Hongjie Yu; Benjamin J Cowling; Luzhao Feng; Eric H Y Lau; Qiaohong Liao; Tim K Tsang; Zhibin Peng; Peng Wu; Fengfeng Liu; Vicky J Fang; Honglong Zhang; Ming Li; Lingjia Zeng; Zhen Xu; Zhongjie Li; Huiming Luo; Qun Li; Zijian Feng; Bin Cao; Weizhong Yang; Joseph T Wu; Yu Wang; Gabriel M Leung
Journal:  Lancet       Date:  2013-06-24       Impact factor: 79.321

10.  Human infection with highly pathogenic avian influenza virus (H5N1) in northern Vietnam, 2004-2005.

Authors:  Nguyen Duc Hien; Nguyen Hong Ha; Nguyen Tuong Van; Nguyen Thi Minh Ha; Trinh Thi Minh Lien; Nguyen Quoc Thai; Van Dinh Trang; Takuro Shimbo; Yoshimitsu Takahashi; Yasuyuki Kato; Akihiko Kawana; Samu Akita; Koichiro Kudo
Journal:  Emerg Infect Dis       Date:  2009-01       Impact factor: 6.883

View more
  12 in total

1.  Evaluation of the Immune Responses to and Cross-Protective Efficacy of Eurasian H7 Avian Influenza Viruses.

Authors:  Hyeok-Il Kwon; Young-Il Kim; Su-Jin Park; Min-Suk Song; Eun-Ha Kim; Se Mi Kim; Young-Jae Si; In-Won Lee; Byung-Min Song; Youn-Jeong Lee; Seok Joong Yun; Wun-Jae Kim; Young Ki Choi
Journal:  J Virol       Date:  2017-05-12       Impact factor: 5.103

2.  H7N9 avian influenza A virus in China: a short report on its circulation, drug resistant mutants and novel antiviral drugs.

Authors:  Bao Danqi; Zejun Li; Qinfang Liu; Juergen A Richt
Journal:  Expert Rev Anti Infect Ther       Date:  2017-07-17       Impact factor: 5.091

3.  Novel influenza A viruses and pandemic threats.

Authors:  Timothy M Uyeki; Jacqueline M Katz; Daniel B Jernigan
Journal:  Lancet       Date:  2017-06-03       Impact factor: 79.321

4.  Recombinant H7 hemagglutinin forms subviral particles that protect mice and ferrets from challenge with H7N9 influenza virus.

Authors:  Peter Pushko; Lindsey M Pujanauski; Xiangjie Sun; Melissa Pearce; Rachmat Hidajat; Thomas Kort; Louis M Schwartzman; Irina Tretyakova; Liu Chunqing; Jeffery K Taubenberger; Terrence M Tumpey
Journal:  Vaccine       Date:  2015-07-21       Impact factor: 3.641

5.  Recombinant Hemagglutinin and Virus-Like Particle Vaccines for H7N9 Influenza Virus.

Authors:  Xiaohui Li; Peter Pushko; Irina Tretyakova
Journal:  J Vaccines Vaccin       Date:  2015-06-30

6.  Effectiveness of traveller screening for emerging pathogens is shaped by epidemiology and natural history of infection.

Authors:  Katelyn M Gostic; Adam J Kucharski; James O Lloyd-Smith
Journal:  Elife       Date:  2015-02-19       Impact factor: 8.140

7.  Improvement of a rapid diagnostic application of monoclonal antibodies against avian influenza H7 subtype virus using Europium nanoparticles.

Authors:  Seon-Ju Yeo; Duong Tuan Bao; Ga-Eun Seo; Cuc Thi Bui; Do Thi Hoang Kim; Nguyen Thi Viet Anh; Trinh Thi Thuy Tien; Nguyen Thi Phuong Linh; Hae-Jin Sohn; Chom-Kyu Chong; Ho-Joon Shin; Hyun Park
Journal:  Sci Rep       Date:  2017-08-11       Impact factor: 4.379

8.  Epidemiological, clinical, and virologic features of two family clusters of avian influenza A (H7N9) virus infections in Southeast China.

Authors:  Jianfeng Xie; Yuwei Weng; Jianming Ou; Lin Zhao; Yanhua Zhang; Jinzhang Wang; Wei Chen; Meng Huang; Wenqiong Xiu; Hongbin Chen; Yongjun Zhang; Binshan Wu; Wenxiang He; Ying Zhu; Libin You; Zhimiao Huang; Canming Zhang; Longtao Hong; Wei Wang; Kuicheng Zheng
Journal:  Sci Rep       Date:  2017-05-04       Impact factor: 4.379

9.  Human H7N9 virus induces a more pronounced pro-inflammatory cytokine but an attenuated interferon response in human bronchial epithelial cells when compared with an epidemiologically-linked chicken H7N9 virus.

Authors:  Kelvin K W To; Candy C Y Lau; Patrick C Y Woo; Susanna K P Lau; Jasper F W Chan; Kwok-Hung Chan; Anna J X Zhang; Honglin Chen; Kwok-Yung Yuen
Journal:  Virol J       Date:  2016-03-15       Impact factor: 4.099

10.  Adequacy of public health communications on H7N9 and MERS in Singapore: insights from a community based cross-sectional study.

Authors:  Yan'an Hou; Yi-Roe Tan; Wei Yen Lim; Vernon Lee; Linda Wei Lin Tan; Mark I-Cheng Chen; Peiling Yap
Journal:  BMC Public Health       Date:  2018-04-02       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.